Loading
A phase 2 trial of abemaciclib, everolimus and capecitabine in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies is a phase 2, interventional study registered as NCT07340541 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 700 participants, started 2026-02-16 and due to reach its primary completion in 2031-06-02. Interventions recorded: SERD* + abemaciclib; SERD* + everolimus; SERD* + everolimus or capecitabine; SOC; Antiandrogen. Conditions listed: Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer; Estrogen-receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma. Sites: United States. No results are recorded here; the registry entry is the source.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.